These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35960952)

  • 1. Use of SGLT-2 Inhibitors to Treat Chronic Kidney Disease in Primary Care.
    Bakris G
    J Fam Pract; 2022 Jul; 71(6 Suppl):S88-S93. PubMed ID: 35960952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Handelsman Y
    Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
    Mende CW
    Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
    Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V
    Diabetes; 2021 Jan; 70(1):1-16. PubMed ID: 33106255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Tsukamoto S; Morita R; Yamada T; Urate S; Azushima K; Uneda K; Kobayashi R; Kanaoka T; Wakui H; Tamura K
    Diabetes Res Clin Pract; 2022 Dec; 194():110161. PubMed ID: 36403681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease.
    Sarafidis P; Pella E; Kanbay M; Papagianni A
    Curr Med Chem; 2023; 30(18):2039-2060. PubMed ID: 36028970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.
    Mende CW
    Curr Med Res Opin; 2017 Mar; 33(3):541-551. PubMed ID: 27977314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
    Solomon J; Festa MC; Chatzizisis YS; Samanta R; Suri RS; Mavrakanas TA
    Pharmacol Ther; 2023 Feb; 242():108330. PubMed ID: 36513134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
    Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
    Yamada T; Wakabayashi M; Bhalla A; Chopra N; Miyashita H; Mikami T; Ueyama H; Fujisaki T; Saigusa Y; Yamaji T; Azushima K; Urate S; Suzuki T; Abe E; Wakui H; Tamura K
    Cardiovasc Diabetol; 2021 Jan; 20(1):14. PubMed ID: 33413348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
    Scheen AJ
    Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sub-analyses of the DAPA-CKD study: new data on the use of sodium-glucose cotransporter type 2 inhibitor in the treatment of chronic kidney disease].
    Shamkhalova MS; Sukhareva OY; Shestakova MV
    Ter Arkh; 2022 Nov; 94(10):1188-1196. PubMed ID: 36468994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice.
    Giaccari A; Pontremoli R; Perrone Filardi P
    Int J Cardiol; 2022 Mar; 351():66-70. PubMed ID: 34979145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
    Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
    Perm J; 2021 May; 25():. PubMed ID: 33970086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
    Davidson JA; Kuritzky L
    Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.